Hasvold, L P <br/><br/>
Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients.  [electronic resource] 

 -  Journal of human hypertension  Nov 2014 
 - 663-9 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5527 
<br/><br/><label>Standard No.: </label>10.1038/jhh.2014.43  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Angiotensin II Type 1 Receptor Blockers--therapeutic use<br/>Angiotensin-Converting Enzyme Inhibitors--therapeutic use<br/>Benzimidazoles--therapeutic use<br/>Biphenyl Compounds<br/>Blood Pressure--drug effects<br/>Cardiovascular Diseases--diagnosis<br/>Diabetes Mellitus, Type 2--diagnosis<br/>Enalapril--therapeutic use<br/>Female<br/>Humans<br/>Hypertension--diagnosis<br/>Incidence<br/>Male<br/>Middle Aged<br/>Primary Health Care<br/>Retrospective Studies<br/>Risk Factors<br/>Sweden--epidemiology<br/>Tetrazoles--therapeutic use<br/>Time Factors<br/>Treatment Outcome